NasdaqGS:MRNABiotechs
Moderna’s TIME Ranking And Combo Vaccine Approval Reshape Growth Question
Moderna (NasdaqGS:MRNA) ranked no. 1 on TIME's 2026 World's Most Impactful Companies list.
The company received European approval for mCOMBRIAX, its first combined flu and COVID vaccine.
These developments expand Moderna's recognized societal role and add a new approved product beyond COVID-only vaccines.
For investors following Moderna, this recognition and new approval come as the company continues to build around its mRNA platform in vaccines and therapeutics. The flu plus COVID product...